Vaxcyte, Inc.
US ˙ NasdaqGS ˙ US92243G1085

SecurityPCVX / Vaxcyte, Inc.
InstitutionStandard Life Aberdeen plc
Latest Disclosed Ownership978,969 shares
Latest Disclosed Value $ 56,887,889
Standard Life Aberdeen plc reports 0.08% decrease in ownership of PCVX / Vaxcyte, Inc.

On April 29, 2026 - Standard Life Aberdeen plc filed a 13F-HR form disclosing ownership of 978,969 shares of Vaxcyte, Inc. (US:PCVX) valued at $56,887,889 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 16, 2026 disclosing 979,765 shares of Vaxcyte, Inc.. This represents a change in shares of -0.08% during the quarter. The current value of the position is $46,363,972 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-04-29 2026-03-31 13F VAXCYTE COM 92243G108 978,969 -796 -0.08 56,888 25.84 0.0498
2026-01-16 2025-12-31 13F VAXCYTE COM 92243G108 979,765 256,972 35.55 45,206 73.64 0.0390
2025-11-07 2025-09-30 13F VAXCYTE COM 92243G108 722,793 297,886 70.11 26,035 88.48 0.0412
2025-07-24 2025-06-30 13F VAXCYTE COM 92243G108 424,907 160,170 60.50 13,814 38.19 0.0235
2025-05-13 2025-03-31 13F VAXCYTE COM 92243G108 264,737 39,913 17.75 9,996 -45.69 0.0195
2025-01-24 2024-12-31 13F VAXCYTE COM 92243G108 224,824 141,994 171.43 18,404 94.46 0.0345
2024-10-25 2024-09-30 13F VAXCYTE COM 92243G108 82,830 -107,571 -56.50 9,465 -34.17 0.0174
2024-08-09 2024-06-30 13F VAXCYTE COM 92243G108 190,401 -3,831 -1.97 14,377 8.37 0.0276
2024-05-09 2024-03-31 13F VAXCYTE COM 92243G108 194,232 0 0.00 13,268 8.77 0.0260
2024-01-31 2023-12-31 13F VAXCYTE COM 92243G108 194,232 194,232 12,198 0.0264
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.